Ray Dalio's VKTX Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 71,229 shares of Viking Therapeutics, Inc. (VKTX) worth $2.32 M, representing 0.01% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 3 quarters.
Based on 13F filings, Ray Dalio has maintained this position in VKTX for several quarters, showing initial confidence in the investment. Largest reduction occurred in Q1 2026, reducing 32,430 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Viking Therapeutics (VKTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Viking Therapeutics (VKTX) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -32,430 | Reduce 31.29% | 71,229 | $32.54 |
| Q4 2025 | -19,832 | Reduce 16.06% | 103,659 | $35.18 |
| Q3 2025 | +123,491 | New Buy | 123,491 | $26.28 |
Ray Dalio's Viking Therapeutics Investment FAQs
Ray Dalio first purchased Viking Therapeutics, Inc. (VKTX) in Q3 2025, acquiring 123,491 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Viking Therapeutics, Inc. (VKTX) for 3 quarters since Q3 2025.
Ray Dalio's largest addition to Viking Therapeutics, Inc. (VKTX) was in Q3 2025, adding 123,491 shares worth $3.25 M.
According to the latest 13F filing for Q1 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 71,229 shares of Viking Therapeutics, Inc. (VKTX), valued at approximately $2.32 M.
As of the Q1 2026 filing, Viking Therapeutics, Inc. (VKTX) represents approximately 0.01% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Viking Therapeutics, Inc. (VKTX) was 123,491 shares, as reported at the end of Q3 2025.